Clinical Trial: A Proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients with Fabry Disease

U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06858397) titled 'A Proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients with Fabry Disease' on Feb. 19.

Brief Summary: This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Fabry Disesase

Intervention: DRUG: HM15421/GC1134A

SC

Recruitment Status: NOT_YET_RECRUITING

Sponsor: GC Biopharma Corp

Disclaimer: Curated by HT Syndication....